Circadian rhythms and new options for novel anticancer therapies

References

• Foster RG, Hankins MW, Peirson SN. Light, . photoreceptors, and circadian clocks. In: Rosato E, editor. Circadian Rhythms. Totowa, NJ: Humana Press; 2007. Methods in Molecular Biology™, 362:3–28.
   Google Scholar
• Sancar A. Regulation of the mammalian circadian clock by cryptochrome. J Biol Chem. 2004;279(33):34079–34082.
   PubMed Web of Science ®Google Scholar
• Okamura H. Suprachiasmatic nucleus clock time in the mammalian circadian system. Cold Spring Harb Symp Quant Biol. 2007;72:551–556.
   PubMedGoogle Scholar
• Weaver DR. The suprachiasmatic nucleus: a 25-year retrospective. J Biol Rhythms. 1998;13(2):100–112.
   PubMed Web of Science ®Google Scholar
• King DP, Zhao Y, Sangoram AM, et al. Positional cloning of the mouse circadian clock gene. Cell. 1997;89(4):641–653.
   PubMed Web of Science ®Google Scholar
• Vitaterna MH, King DP, Chang AM, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science. 1994;264(5159):719–725.
   PubMed Web of Science ®Google Scholar
• Bunger MK, Wilsbacher LD, Moran SM, et al. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell. 2000;103(7):1009–1017.
   PubMed Web of Science ®Google Scholar
• Sangoram AM, Saez L, Antoch MP, et al. Mammalian mircadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998;21(5):1101–1113.
   Web of Science ®Google Scholar
• Lee C, Etchegaray J-P, Cagampang FRA, Loudon ASI, Reppert SM. Posttranslational mechanisms regulate the mammalian circadian clock. Cell. 2001;107(7):855–867.
   PubMed Web of Science ®Google Scholar
• Shearman LP, Jin X, Lee C, Reppert SM, Weaver DR. Targeted disruption of the mPer3 gene: subtle effects on circadian clock function. Mol Cell Biol. 2000;20(17):6269–6275.
   PubMed Web of Science ®Google Scholar
• Akashi M, Tsuchiya Y, Yoshino T, Nishida E. Control of intracellular dynamics of mammalian period proteins by casein kinase I ε (CKIε) and CKIδ in cultured cells. Mol Cell Biol. 2002;22(6):1693–1703.
   PubMed Web of Science ®Google Scholar
• Xu Y, Padiath QS, Shapiro RE, et al. Functional consequences of a CKIδ mutation causing familial advanced sleep phase syndrome. Nature. 2005;434(7033):640–644.
   PubMed Web of Science ®Google Scholar
• Bieler J, Cannavo R, Gustafson K, Gobet C, Gatfield D, Naef F. Robust synchronization of coupled circadian and cell cycle oscillators in single mammalian cells. Mol Syst Biol. 2014;10(7):739.
   Web of Science ®Google Scholar
• Hahn AT, Jones JT, Meyer T. Quantitative analysis of cell cycle phase durations and PC12 differentiation using fluorescent biosensors. Cell Cycle. 2009;8(7):1044–1052.
   PubMed Web of Science ®Google Scholar
• Mori T, Binder B, Johnson CH. Circadian gating of cell division in cyanobacteria growing with average doubling times of less than 24 hours. Proc Natl Acad Sci. 1996;93(19):10183–10188.
   PubMed Web of Science ®Google Scholar
• Hong CI, Zámborszky J, Baek M, et al. Circadian rhythms synchronize mitosis in Neurospora crassa. Proc Natl Acad Sci. 2014;111(4):1397–1402.
   Web of Science ®Google Scholar
• Tamai TK, Young LC, Cox CA, Whitmore D. Light acts on the zebrafish circadian clock to suppress rhythmic mitosis and cell proliferation. J Biol Rhythms. 2012;27(3):226–236.
   Web of Science ®Google Scholar
• Brown WR. A review and mathematical analysis of circadian rhythms in cell proliferation in mouse, rat, and human epidermis. J Invest Dermatol. 1991;97(2):273–280.
   PubMed Web of Science ®Google Scholar
• Kowalska E, Ripperger JA, Hoegger DC, et al. NONO couples the circadian clock to the cell cycle. Proc Natl Acad Sci. 2013;110(5):1592–1599.
   Web of Science ®Google Scholar
• Bjarnason GA, Jordan RCK, Wood PA, et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol. 2001;158(5):1793–1801.
   PubMed Web of Science ®Google Scholar
• Masri S, Cervantes M, Sassone-Corsi P. The circadian clock and cell cycle: interconnected biological circuits. Curr Opin Cell Biol. 2013;25(6):730–734.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302(5643):255–259.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Maiuri MC, Vitale I, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14(7):1237–1243.
   PubMed Web of Science ®Google Scholar
• Mansilla S, Bataller M, Portugal J. Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med Chem. 2006;6(6):589–602.
   Google Scholar
• Hoogerwerf WA. Biologic clocks and the gut. Curr Gastroenterol Rep. 2006;8(5):353–359.
   PubMedGoogle Scholar
• Geyfman M, Andersen B. Clock genes, hair growth and aging. Aging. 2010;2(3):122–128.
   Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73–112.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375–382.
   PubMed Web of Science ®Google Scholar
• Barnes JW, Tischkau SA, Barnes JA, et al. Requirement of mammalian timeless for circadian rhythmicity. Science. 2003;302(5644):439–442.
   PubMed Web of Science ®Google Scholar
• Ünsal-Kaçmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005;25(8):3109–3116.
   PubMed Web of Science ®Google Scholar
• Kanai S, Kikuno R, Toh H, Ryo H, Todo T. Molecular evolution of the photolyase-blue-light photoreceptor family. J Mol Evol. 1997;45(5):535–548.
   Web of Science ®Google Scholar
• Chaves I, Nijman RM, Biernat MA, et al. The Potorous CPD photolyase rescues a cryptochrome-deficient mammalian circadian clock. PLoS One. 2011;6(8):e23447.
   Web of Science ®Google Scholar
• Kang T-H, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci. 2009;106(8):2864–2867.
   PubMed Web of Science ®Google Scholar
• Kang T-H, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci. 2010;107(11):4890–4895.
   PubMed Web of Science ®Google Scholar
• Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci. 2011;108(46):18790–18795.
   Web of Science ®Google Scholar
• Cotta-Ramusino C, McDonald ER, Hurov K, Sowa ME, Harper JW, Elledge SJ. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science. 2011;332(6035):1313–1317.
   PubMed Web of Science ®Google Scholar
• Kang T-H, Sancar A. Circadian regulation of DNA excision repair: implications for chrono-chemotherapy. Cell Cycle. 2009;8(11):1665–1667.
   PubMed Web of Science ®Google Scholar
• Antoch MP, Kondratov RV. Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy. In: Kramer A, Merrow M, editors. Circadian Clocks. Berlin: Springer; 2013. Handbook of Experimental Pharmacology, 217:289–309.
   Google Scholar
• Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50(1):377–421.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Panza A, Valvano MR, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011;28(10):841–851.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hua L, Lu C, Chen Z. Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. World J Surg Oncol. 2011;9(1):166.
   Google Scholar
• Eisele L, Prinz R, Klein-Hitpass L, et al. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol. 2009;83(4):320–327.
   PubMed Web of Science ®Google Scholar
• Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87(10):1060–1070.
   PubMed Web of Science ®Google Scholar
• Yi C, Mu L, de la Longrais IAR, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat. 2010;120(3):663–669.
   PubMed Web of Science ®Google Scholar
• Chu LW, Zhu Y, Yu K, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 2007;11(4):342–348.
   Web of Science ®Google Scholar
• Zhu Y, Stevens RG, Leaderer D, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat. 2008;107(3):421–425.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Stevens RG, et al. Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res. 2009;69(8):3605–3613.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Theodoropoulos G, Gazouli M, et al. Association of the clock genes polymorphisms with colorectal cancer susceptibility. J Surg Oncol. 2013;108(8):563–567.
   PubMed Web of Science ®Google Scholar
• Chen S-T, Choo K-B, Hou M-F, Yeh K-T, Kuo S-J, Chang J-G. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26(7):1241–1246.
   PubMed Web of Science ®Google Scholar
• Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann W-K, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood. 2005;106(8):2827–2836.
   PubMed Web of Science ®Google Scholar
• Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007;26(57):7916–7920.
   PubMed Web of Science ®Google Scholar
• Guess J, Burch JB, Ogoussan K, et al. Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther. 2009;8(4):329–336.
   Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee CC. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111(1):41–50.
   PubMed Web of Science ®Google Scholar
• Wood PA, Yang X, Taber A, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008;6(11):1786–1793.
   PubMed Web of Science ®Google Scholar
• Yang X, Wood PA, Ansell CM, et al. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem (Tokyo). 2009;145(3):289–297.
   PubMed Web of Science ®Google Scholar
• Yang X, Wood PA, Oh E-Y, Du-Quiton J, Ansell CM, Hrushesky WJM. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 2009;117(2):423–431.
   PubMed Web of Science ®Google Scholar
• Hua H, Wang Y, Wan C, et al. Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther. 2007;14(9):815–818.
   Web of Science ®Google Scholar
• Yang X, Wood PA, Ansell CM, et al. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009;26(7):1323–1339.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Kim L, Kang S-G, et al. PER2 variation is associated with diurnal preference in a Korean Young Population. Behav Genet. 2011;41(2):273–277.
   Web of Science ®Google Scholar
• Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005;14(1):268–270.
   PubMed Web of Science ®Google Scholar
• Soták M, Polidarová L, Ergang P, Sumová A, Pácha J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 2013;132(5):1032–1041.
   PubMed Web of Science ®Google Scholar
• Sahar S, Zocchi L, Kinoshita C, Borrelli E, Sassone-Corsi P. Regulation of BMAL1 protein stability and circadian function by GSK3β-mediated phosphorylation. PLoS One. 2010;5(1):e8561.
   PubMed Web of Science ®Google Scholar
• Chen J, Huang X-F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther. 2009;8(14):1313–1317.
   PubMed Web of Science ®Google Scholar
• Relógio A, Thomas P, Medina-Pérez P, et al. Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 2014;10(5):e1004338.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. IARC Monogarphs Painting, Firefighting and Shift Work. Lyon France: International Agency for Research on Cancer; 2010.
   Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293(5532):1074–1080.
   PubMed Web of Science ®Google Scholar
• Crosio C, Cermakian N, Allis CD, Sassone-Corsi P. Light induces chromatin modification in cells of the mammalian circadian clock. Nat Neurosci. 2000;3(12):1241–1247.
   Web of Science ®Google Scholar
• Ripperger JA, Schibler U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet. 2006;38(3):369–374.
   PubMed Web of Science ®Google Scholar
• Etchegaray J-P, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature. 2003;421(6919):177–182.
   PubMed Web of Science ®Google Scholar
• Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell. 2006;125(3):497–508.
   PubMed Web of Science ®Google Scholar
• Hirayama J, Sahar S, Grimaldi B, et al. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature. 2007;450(7172):1086–1090.
   PubMed Web of Science ®Google Scholar
• Katada S, Sassone-Corsi P. The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. Nat Struct Mol Biol. 2010;17(12):1414–1421.
   PubMed Web of Science ®Google Scholar
• Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134(2):317–328.
   PubMed Web of Science ®Google Scholar
• Bishop NA, Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 2007;8(11):835–844.
   Web of Science ®Google Scholar
• Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324(5927):654–657.
   PubMed Web of Science ®Google Scholar
• Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008;7(2):104–112.
   Web of Science ®Google Scholar
• Feng D, Liu T, Sun Z, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011;331(6022):1315–1319.
   PubMed Web of Science ®Google Scholar
• Duong HA, Robles MS, Knutti D, Weitz CJ. A molecular mechanism for circadian clock negative feedback. Science. 2011;332(6036):1436–1439.
   PubMed Web of Science ®Google Scholar
• Shaknovich R, De S, Michor F. Epigenetic diversity in hematopoietic neoplasms. Biochim Biophys Acta BBA – Rev Cancer. 2014;1846(2):477–484.
   Web of Science ®Google Scholar
• Nakamura J. Methylation-mediated gene silencing as biomarkers of gastric cancer: a review. World J Gastroenterol. 2014;20(34):11991.
   Web of Science ®Google Scholar
• Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes. 2014;5(3):821–864.
   PubMed Web of Science ®Google Scholar
• Newton K, Jorgensen NM, Wallace AJ, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet. Epub October 13, 2014.
   Google Scholar
• Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–299.
   PubMed Web of Science ®Google Scholar
• Kino T, Chrousos GP. Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol. 2011;336(1–2):23–30.
   PubMed Web of Science ®Google Scholar
• Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–1363.
   PubMed Web of Science ®Google Scholar
• Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med. 2006;203(1):7–13.
   PubMed Web of Science ®Google Scholar
• Nader N, Chrousos GP, Kino T. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. FASEB J. 2009;23(5):1572–1583.
   PubMed Web of Science ®Google Scholar
• Nader N, Chrousos GP, Kino T. Interactions of the circadian CLOCK system and the HPA axis. Trends Endocrinol Metab. 2010; 21(5):277–286.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148.
   PubMed Web of Science ®Google Scholar
• Li D, Bi F-F, Chen N-N, et al. A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer. Sci Rep. 2014;4:6666.
   Web of Science ®Google Scholar
• Teboul M, Guillaumond F, Gréchez-Cassiau A, Delaunay F. Minireview: the nuclear hormone receptor family round the clock. Mol Endocrinol. 2008;22(12):2573–2582.
   Google Scholar
• Coumoul X, Diry M, Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol. 2002;64(10):1513–1519.
   PubMed Web of Science ®Google Scholar
• Ourlin JC, Lasserre F, Pineau T, et al. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol. 2003;17(9):1693–1703.
   Google Scholar
• Oiwa A, Kakizawa T, Miyamoto T, et al. Synergistic regulation of the mouse orphan nuclear receptor SHP gene promoter by CLOCK–BMAL1 and LRH-1. Biochem Biophys Res Commun. 2007;353(4):895–901.
   PubMed Web of Science ®Google Scholar
• Dioum EM, Rutter J, Tuckerman JR, Gonzalez G, Gilles-Gonzalez M-A, McKnight SL. NPAS2: a gas-responsive transcription factor. Science. 2002;298(5602):2385–2387.
   PubMed Web of Science ®Google Scholar
• Claudel T, Cretenet G, Saumet A, Gachon F. Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 2007;581(19):3626–3633.
   PubMed Web of Science ®Google Scholar
• Zhang Y-KJ, Yeager RL, Klaassen CD. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos. 2009;37(1):106–115.
   PubMed Web of Science ®Google Scholar
• Takiguchi T, Tomita M, Matsunaga N, Nakagawa H, Koyanagi S, Ohdo S. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics. 2007;17(12):1047–1056.
   Web of Science ®Google Scholar
• Zmrzljak UP, Rozman D. Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters. Chem Res Toxicol. 2012;25(4):811–824.
   Web of Science ®Google Scholar
• Zuber AM, Centeno G, Pradervand S, et al. Molecular clock is involved in predictive circadian adjustment of renal function. Proc Natl Acad Sci. 2009;106(38):16523–16528.
   PubMed Web of Science ®Google Scholar
• Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006;4(1):25–36.
   PubMed Web of Science ®Google Scholar
• Gorbacheva VY, Kondratov RV, Zhang R, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005;102(9):3407–3412.
   PubMed Web of Science ®Google Scholar
• Storch K-F, Lipan O, Leykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002;417(6884):78–83.
   PubMed Web of Science ®Google Scholar
• Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.
   PubMed Web of Science ®Google Scholar
• Li X-M, Metzger G, Filipski E, et al. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol. 1997;143(2):281–290.
   PubMed Web of Science ®Google Scholar
• Li XM, Metzger G, Filipski E, Lemaigre G, Lévi F. Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice. Arch Toxicol. 1998;72(9):574–579.
   Web of Science ®Google Scholar
• Labrecque G, Bélanger PM. Basic mechanisms of chronopharmacology [In French]. Pathol Biol (Paris). 1987;35(6):917–923.
   Google Scholar
• Boughattas NA, Lévi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res. 1989;49(12):3362–3368.
   PubMed Web of Science ®Google Scholar
• Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 1998;93(6):929–937.
   PubMed Web of Science ®Google Scholar
• Balsalobre A, Brown SA, Marcacci L, et al. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science. 2000;289(5488):2344–2347.
   PubMed Web of Science ®Google Scholar
• Yagita K, Okamura H. Forskolin induces circadian gene expression of rPer1, rPer2 and dbp in mammalian rat-1 fibroblasts. FEBS Lett. 2000;465(1):79–82.
   PubMed Web of Science ®Google Scholar
• Balsalobre A, Marcacci L, Schibler U. Multiple signaling pathways elicit circadian gene expression in cultured Rat-1 fibroblasts. Curr Biol. 2000;10(20):1291–1294.
   PubMed Web of Science ®Google Scholar
• Yagita K, Tamanini F, van der Horst GTJ, Okamura H. Molecular mechanisms of the biological clock in cultured fibroblasts. Science. 2001;292(5515):278–281.
   PubMed Web of Science ®Google Scholar
• Hirota T, Okano T, Kokame K, Shirotani-Ikejima H, Miyata T, Fukada Y. Glucose down-regulates Per1 and Per2mRNA levels and induces circadian gene expression in cultured rat-1 fibroblasts. J Biol Chem. 2002;277(46):44244–44251.
   Web of Science ®Google Scholar
• Tsuchiya Y, Minami I, Kadotani H, Nishida E. Resetting of peripheral circadian clock by prostaglandin E2. EMBO Rep. 2005;6(3):256–261.
   Web of Science ®Google Scholar
• Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009;324(5927):651–654.
   PubMed Web of Science ®Google Scholar
• Raghuram S, Stayrook KR, Huang P, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ. Nat Struct Mol Biol. 2007;14(12):1207–1213.
   PubMed Web of Science ®Google Scholar
• O’Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science. 2008;320(5878):949–953.
   Web of Science ®Google Scholar
• Izumo M, Sato TR, Straume M, Johnson CH. Quantitative analyses of circadian gene expression in mammalian cell cultures. PLoS Comput Biol. 2006;2(10):e136.
   PubMed Web of Science ®Google Scholar
• Hirota T, Lewis WG, Liu AC, Lee JW, Schultz PG, Kay SA. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proc Natl Acad Sci. 2008;105(52):20746–20751.
   PubMed Web of Science ®Google Scholar
• Harada Y, Sakai M, Kurabayashi N, Hirota T, Fukada Y. Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3β. J Biol Chem. 2005;280(36):31714–31721.
   Web of Science ®Google Scholar
• Iitaka C, Miyazaki K, Akaike T, Ishida N. A Role for glycogen synthase kinase-3β in the mammalian circadian clock. J Biol Chem. 2005;280(33):29397–29402.
   Web of Science ®Google Scholar
• Spengler ML, Kuropatwinski KK, Schumer M, Antoch M. A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation. Cell Cycle. 2009;8(24):4138–4146.
   PubMed Web of Science ®Google Scholar
• Yin L, Wang J, Klein PS, Lazar MA. Nuclear receptor Rev-erbα is a critical lithium-sensitive component of the circadian clock. Science. 2006;311(5763):1002–1005.
   PubMed Web of Science ®Google Scholar
• Hirota T, Lee JW, Lewis WG, et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010;8(12):e1000559.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yoo S-H, Park Y-S, et al. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. Proc Natl Acad Sci. 2012;109(1):101–106.
   PubMed Web of Science ®Google Scholar
• Hirota T, Lee JW, John PCS, et al. Identification of small molecule activators of cryptochrome. Science. 2012;337(6098):1094–1097.
   PubMed Web of Science ®Google Scholar
• Lamia KA, Papp SJ, Yu RT, et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature. 2011;480(7378):552–556.
   PubMed Web of Science ®Google Scholar
• Zhang EE, Liu Y, Dentin R, et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med. 2010;16(10):1152–1156.
   PubMed Web of Science ®Google Scholar
• Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging. 2011;3(5):479–493.
   PubMedGoogle Scholar
• Hu Y, Spengler ML, Kuropatwinski KK, et al. Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget. 2011;2(12):1279–1290.
   PubMedGoogle Scholar
• Antoch MP, Chernov MV. Pharmacological modulators of the circadian clock as potential therapeutic drugs. Mutat Res. 2009;680(1–2):109–115.
   Web of Science ®Google Scholar
• Gehrisch A, Dörr PDW. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol. 2007;183(1):36–42.
   Web of Science ®Google Scholar
• Muecke R, Schomburg L, Glatzel M, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol. 2010;78(3):828–835.
   Web of Science ®Google Scholar
• Ozturk N, Lee JH, Gaddameedhi S, Sancar A. Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci. 2009;106(8):2841–2846.
   PubMed Web of Science ®Google Scholar
• Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ. 2006;14(3):436–446.
   Web of Science ®Google Scholar
• Lee JH, Sancar A. Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proc Natl Acad Sci. 2011;108(26):10668–10672.
   Web of Science ®Google Scholar
• Lévi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv. 2011;8(12):1535–1541.
   PubMed Web of Science ®Google Scholar
• Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893–900.
   PubMed Web of Science ®Google Scholar
• Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res. 1993;53(7):1534–1537.
   PubMed Web of Science ®Google Scholar
• Rivard GE, Infante-Rivard C, Dresse MF, Leclerc JM, Champagne J. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol Int. 1993;10(3):201–204.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi M-C, Cardot J-M, François E, et al. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin Pharmacol Ther. 2007;83(3):413–415.
   Web of Science ®Google Scholar
• Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F. Prednisone chronotherapy. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S42–S45.
   PubMed Web of Science ®Google Scholar
• Sothern RB, Lévi F, Haus E, Halberg F, Hrushesky WJ. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989;81(2):135–145.
   PubMedGoogle Scholar
• Granda TG, D’Attino R-M, Filipski E, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer. 2002;86(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Li XM, Tanaka K, Sun J, et al. Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin. Br J Cancer. 2005;92(9):1684–1689.
   PubMed Web of Science ®Google Scholar
• Granda TG, Filipski E, D’Attino RM, et al. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res. 2001;61(5):1996–2001.
   PubMed Web of Science ®Google Scholar
• Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F. Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother. 1995;5(3 Suppl 1):148–152.
   PubMedGoogle Scholar
• Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985;228(4695):73–75.
   PubMed Web of Science ®Google Scholar
• Lévi F, Benavides M, Chevelle C, et al. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol Off J Am Soc Clin Oncol. 1990;8(4):705–714.
   PubMed Web of Science ®Google Scholar
• Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82(12):1046–1050.
   PubMed Web of Science ®Google Scholar
• Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29A(9):1280–1284.
   Web of Science ®Google Scholar
• Lévi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86(21):1608–1617.
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350(9079):681–686.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006;24(22):3562–3569.
   PubMed Web of Science ®Google Scholar
• Ahowesso C, Piccolo E, Li XM, et al. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett. 2010;192(3):395–401.
   Web of Science ®Google Scholar
• Okyar A, Piccolo E, Ahowesso C, et al. Strain- and sex-dependent circadian changes in Abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One. 2011;6(6):e20393.
   PubMed Web of Science ®Google Scholar
• Jeffrey Wang BSP, Ying Huang BSP. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol. 2007;4(1):59–68.
   Google Scholar
• Bur IM, Cohen-Solal AM, Carmignac D, et al. The circadian clock components CRY1 and CRY2 are necessary to sustain sex dimorphism in mouse liver metabolism. J Biol Chem. 2009;284(14):9066–9073.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Moreau T, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin–5-fluorouracil–leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011;28(7):586–600.
   PubMed Web of Science ®Google Scholar
• Bouchahda M, Adam R, Giacchetti S, et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009;115(21):4990–4999.
   Web of Science ®Google Scholar
• Bjarnason GA, MacKenzie RG, Nabid A, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol. 2009;73(1):166–172.
   Web of Science ®Google Scholar
• Rahn DA, Ray DK, Schlesinger DJ, et al. Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer. 2011;117(2):414–420.
   Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54(8):721–728.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Sothern RB, Parrella P, et al. Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. Clin Exp Med. 2012;12(3):181–194.
   Web of Science ®Google Scholar
• Suzuki S, Toyabe S, Moroda T, et al. Circadian rhythm of leucocytes and lymphocyte subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol. 1997;110(3):500–508.
   PubMed Web of Science ®Google Scholar
• Bollinger T, Leutz A, Leliavski A, et al. Circadian clocks in mouse and human CD4+ T cells. PLoS One. 2011;6(12):e29801.
   PubMed Web of Science ®Google Scholar
• Roenneberg T, Kuehnle T, Juda M, et al. Epidemiology of the human circadian clock. Sleep Med Rev. 2007;11(6):429–438.
   PubMed Web of Science ®Google Scholar
• Chevalier V, Mormont M-C, Curé H, Chollet P. Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer. Oncol Rep. 2003;10(3):733–737.
   Web of Science ®Google Scholar
• Mormont M-C, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and cood performance status. Clin Cancer Res. 2000;6(8):3038–3045.
   PubMed Web of Science ®Google Scholar
• Grutsch JF, Wood PA, Du-Quiton J, et al. Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer. J Circadian Rhythms. 2011;9:4.
   PubMedGoogle Scholar
• Waterhouse J, Drust B, Weinert D, et al. The circadian rhythm of core temperature: origin and some implications for exercise performance. Chronobiol Int. 2005;22(2):207–225.
   PubMed Web of Science ®Google Scholar
• Sarabia JA, Rol MA, Mendiola P, Madrid JA. Circadian rhythm of wrist temperature in normal-living subjects: a candidate of new index of the circadian system. Physiol Behav. 2008;95(4):570–580.
   PubMed Web of Science ®Google Scholar
• Ortiz-Tudela E, Martinez-Nicolas A, Campos M, Rol MÁ, Madrid JA. A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol. 2010;6(11):e1000996.
   PubMed Web of Science ®Google Scholar
• Hardeland R, Madrid JA, Tan D-X, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012;52(2):139–166.
   PubMed Web of Science ®Google Scholar
• Clow A, Hucklebridge F, Thorn L. The cortisol awakening response in context. In: Clow A, Thorn L, editors. Science of Awakening. New York, NY: Academic Press; 2010. International Review of Neurobiology, 93:153–175.
   Google Scholar
• Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004;29(8):1082–1092.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000.
   PubMedGoogle Scholar
• Weinrib AZ, Sephton SE, DeGeest K, et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010;116(18):4410–4419.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Lush E, Dedert EA, et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 2013;30(Suppl):S163–S170.
   PubMedGoogle Scholar
• Mormont M-C, Langouët AM, Claustrat B, et al. Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int. 2002;19(1):141–155.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Focan C, Gorlia T, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009;69(11):4700–4707.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Rissling M, Neikrug A, et al. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer. 2012;20(6):1211–1219.
   PubMed Web of Science ®Google Scholar
• Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293–303.
   PubMed Web of Science ®Google Scholar